Skip to main content
OpenTrials
Completed

NCT Number: NCT05553054

Drug Wastage : Observational Study in Intensive Care Units in France

Environmental awareness leads medical field to question its responsibility and possibilities for action.

Drug residues can have a major environmental impact as per their bioaccumulation, toxicity and persistence characteristics, depending on where they are discarded. In France, drug residues should be disposed of by incineration, but in practice, this is not systematic. Moreover, data on drug wastage in Intensive Care Units (ICU) are rare.

GAME-OVER observational study aims to evaluate drug wastage in ICU in France and to suggest ways to improve health care practices.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Drug Use

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Centre Hospitalier de Charleville-Mezieres, Charleville-Mézières, Ardennes, France

Loading trial locations.

About this study

Observational study with data collection during a 24-hour business day. Data collected refer to healthcare team's practices and patients.

Collection starts when day shift starts (at 7:00 am) and ends when night shift leaves (at 7:00 am the following day).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients hospitalized in intensive care units during the 24 hours of data collection.

Exclusion criteria

  • Patient's opposition to participate in the study or patient family opposition if the patient is not able to be informed.

Treatment and study plan

Quantification of IV drugs wastage

Other

Drugs are prescribed depending on physician discretion.

Specific collection bins are provided to ICU. Healthcare teams discard syringes labelled with name and dilution which have been used to prepare drugs into these bins. After 24 hours of collection, bins are analyzed by investigators.

Primary outcomes

  1. Ratio of overall wastage in milliliter (mL) of prepared and discarded IV drugs to overall volume in milliliter (mL) of prepared IV drugs.

    Time frame: 24 hours

    Wastage is defined as any prepared and unused drug that remains in syringe or IV bag.

Secondary outcomes

  1. Reason for discarding drug residues

    Time frame: 24 hours

    A questionnaire will be fulfilled by healthcare teams with the following possible categories:

    1/ prepared in advance and not used ; 2/ systematic change at fixed times ; 3/ prescription change ; 4/ change by anticipation of care ; 5/ drug no longer needed ; 6/ preparation error ; 7/ other reason.

  2. Drug residues discarding process

    Time frame: 24 hours

    A questionnaire will be used to determine which discarding process are applied by nurses in their usual pratices.

  3. Use of enteral administration route

    Time frame: 24 hours

    Use of enteral administration route versus per os and IV routes will be analyzed for paracetamol and proton pump inhibitor according to the accessibility of enteral route and the reason and the date of patient entry in ICU.

  4. Cost of overall IV drug wastage

    Time frame: 24 hours

    Estimated cost of drug residues will be evaluated for each drug, according to the reason for discarding, by the following formula :

    volume of discarded IV drugs x theoretical price

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer

Other

Collaborators

  • Sainte-Anne Military Teaching Hospital

Registry information

Acronym: GAME-OVER

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Sep 23, 2022
Registry last updated
Jul 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.